MedTrace Logo

An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults

NCT02446314 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2019-08-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether a 6 month dietary intervention with wild blueberry powder and extract stabilised with L-cysteine and L-glutathione have an effect on cognitive performance in participants aged between 65 - 80.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen

DIETARY_SUPPLEMENT

Wild Blueberry Powder - 450mg

Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen

DIETARY_SUPPLEMENT

Wild Blueberry Powder - 900 mg

Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen

DIETARY_SUPPLEMENT

Wild Blueberry extract 100mg

Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen

Sponsors & Collaborators

  • Naurex, Inc, an affiliate of Allergan plc

    collaborator INDUSTRY

  • University of Reading

    lead OTHER

Principal Investigators

  • Claire M Williams, PhD · University of Reaiding

  • Emilie Fromentin, PhD · NATURIEX-DBS,, LLC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-11-30
Completion
2017-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02446314 on ClinicalTrials.gov